272 related articles for article (PubMed ID: 31856726)
1. Prediction of novel mouse TLR9 agonists using a random forest approach.
Khanna V; Li L; Fung J; Ranganathan S; Petrovsky N
BMC Mol Cell Biol; 2019 Dec; 20(Suppl 2):56. PubMed ID: 31856726
[TBL] [Abstract][Full Text] [Related]
2. Single Stranded DNA Immune Modulators with Unmethylated CpG Motifs: Structure and Molecular Recognition by Toll-Like Receptor 9.
Fehér K
Curr Protein Pept Sci; 2019; 20(11):1060-1068. PubMed ID: 31470785
[TBL] [Abstract][Full Text] [Related]
3. Immunostimulatory Properties of Lipid Modified CpG Oligonucleotides.
Yu C; An M; Li M; Liu H
Mol Pharm; 2017 Aug; 14(8):2815-2823. PubMed ID: 28686452
[TBL] [Abstract][Full Text] [Related]
4. Nuclease-resistant immunostimulatory phosphodiester CpG oligodeoxynucleotides as human Toll-like receptor 9 agonists.
Meng W; Yamazaki T; Nishida Y; Hanagata N
BMC Biotechnol; 2011 Sep; 11():88. PubMed ID: 21943407
[TBL] [Abstract][Full Text] [Related]
5. Immunostimulatory Activities of CpG-Oligodeoxynucleotides in Teleosts: Toll-Like Receptors 9 and 21.
Lai CY; Yu GY; Luo Y; Xiang R; Chuang TH
Front Immunol; 2019; 10():179. PubMed ID: 30800129
[TBL] [Abstract][Full Text] [Related]
6. Novel oligodeoxynucleotide agonists of TLR9 containing N3-Me-dC or N1-Me-dG modifications.
Putta MR; Zhu F; Li Y; Bhagat L; Cong Y; Kandimalla ER; Agrawal S
Nucleic Acids Res; 2006; 34(11):3231-8. PubMed ID: 16798912
[TBL] [Abstract][Full Text] [Related]
7. Structure-dependent immunostimulatory effect of CpG oligodeoxynucleotides and their delivery system.
Hanagata N
Int J Nanomedicine; 2012; 7():2181-95. PubMed ID: 22619554
[TBL] [Abstract][Full Text] [Related]
8. Agonists of Toll-like receptor 9 containing synthetic dinucleotide motifs.
Yu D; Putta MR; Bhagat L; Li Y; Zhu F; Wang D; Tang JX; Kandimalla ER; Agrawal S
J Med Chem; 2007 Dec; 50(25):6411-8. PubMed ID: 17988082
[TBL] [Abstract][Full Text] [Related]
9. Monomeric G-Quadruplex-Based CpG Oligodeoxynucleotides as Potent Toll-Like Receptor 9 Agonists.
Tu ATT; Hoshi K; Ikebukuro K; Hanagata N; Yamazaki T
Biomacromolecules; 2020 Sep; 21(9):3644-3657. PubMed ID: 32857497
[TBL] [Abstract][Full Text] [Related]
10. Therapeutic applications of synthetic CpG oligodeoxynucleotides as TLR9 agonists for immune modulation.
Jurk M; Vollmer J
BioDrugs; 2007; 21(6):387-401. PubMed ID: 18020622
[TBL] [Abstract][Full Text] [Related]
11. Construction of Monomeric and Dimeric G-Quadruplex-Structured CpG Oligodeoxynucleotides for Enhanced Uptake and Activation in TLR9-Positive Macrophages.
Liao W; Tan M; Kusamori K; Takakura Y; Nishikawa M
Nucleic Acid Ther; 2020 Oct; 30(5):299-311. PubMed ID: 32559406
[TBL] [Abstract][Full Text] [Related]
12. Necessity of oligonucleotide aggregation for toll-like receptor 9 activation.
Wu CC; Lee J; Raz E; Corr M; Carson DA
J Biol Chem; 2004 Aug; 279(32):33071-8. PubMed ID: 15184382
[TBL] [Abstract][Full Text] [Related]
13. CpG ODNs treatments of HIV-1 infected patients may cause the decline of transmission in high risk populations - a review, hypothesis and implications.
Becker Y
Virus Genes; 2005 Mar; 30(2):251-66. PubMed ID: 15744581
[TBL] [Abstract][Full Text] [Related]
14. Effects of G-Quadruplex Ligands on the Topology, Stability, and Immunostimulatory Properties of G-Quadruplex-Based CpG Oligodeoxynucleotides.
Tu ATT; Hoshi K; Ma Y; Oyama T; Suzuki S; Tsukakoshi K; Nagasawa K; Ikebukuro K; Yamazaki T
ACS Chem Biol; 2022 Jul; 17(7):1703-1713. PubMed ID: 35765965
[TBL] [Abstract][Full Text] [Related]
15. Synthetic methylated CpG ODNs are potent in vivo adjuvants when delivered in liposomal nanoparticles.
Chikh G; de Jong SD; Sekirov L; Raney SG; Kazem M; Wilson KD; Cullis PR; Dutz JP; Tam YK
Int Immunol; 2009 Jul; 21(7):757-67. PubMed ID: 19502586
[TBL] [Abstract][Full Text] [Related]
16. Activation of rabbit TLR9 by different CpG-ODN optimized for mouse and human TLR9.
Liu J; Xu C; Liu YL; Matsuo H; Hsieh RP; Lo JF; Tseng PH; Yuan CJ; Luo Y; Xiang R; Chuang TH
Comp Immunol Microbiol Infect Dis; 2012 Sep; 35(5):443-51. PubMed ID: 22560893
[TBL] [Abstract][Full Text] [Related]
17. Tuning CpG motif position in nanostructured DNA for efficient immune stimulation.
Tan M; Makiguchi N; Kusamori K; Itakura S; Takahashi Y; Takakura Y; Nishikawa M
Biotechnol J; 2024 Apr; 19(4):e2300308. PubMed ID: 38651249
[TBL] [Abstract][Full Text] [Related]
18. CpG oligodeoxynucleotides as TLR9 agonists: therapeutic application in allergy and asthma.
Gupta GK; Agrawal DK
BioDrugs; 2010 Aug; 24(4):225-35. PubMed ID: 20623989
[TBL] [Abstract][Full Text] [Related]
19. CpG oligodeoxynucleotides block human immunodeficiency virus type 1 replication in human lymphoid tissue infected ex vivo.
Schlaepfer E; Audigé A; von Beust B; Manolova V; Weber M; Joller H; Bachmann MF; Kundig TM; Speck RF
J Virol; 2004 Nov; 78(22):12344-54. PubMed ID: 15507621
[TBL] [Abstract][Full Text] [Related]
20. The effect of TLR9 agonist CpG oligodeoxynucleotides on the intestinal immune response of cobia (Rachycentron canadum).
Byadgi O; Puteri D; Lee JW; Chang TC; Lee YH; Chu CY; Cheng TC
J Immunol Res; 2014; 2014():273284. PubMed ID: 24991578
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
